Prevalence of human papillomavirus antibodies in young female subjects in England (British Journal of Cancer (2007) 97, (989-991) DOI: 10.1038/sj.bjc.6603955);Prevalence of human papillomavirus antibodies in young female subjects in England

British Journal of Cancer

Volumn 97, Issue 7, 2007, Pages 989-991

  Jit, M ^a   Vyse, A ^a   Borrow, R ^a   Pebody, R ^a   Soldan, K ^a   Miller, E ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

England; Female; Papillomavirus, human; Seroepidemiologic studies

Indexed keywords

VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SEROPREVALENCE; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; WART VIRUS;

EID: 34948880712     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604403     Document Type: Erratum

References (17)

1. af Geijersstam V, Eklund C, Wang Z, Sapp M, Schiller JT, Dillner J, Dillner L (1999) A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer 80: 489-493
2. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA (2000) Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181: 1911-1919
3. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT (2005) Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 12: 959-969
4. Dillner J (1999) The serological response to papillomaviruses. Semin Cancer Biol 9: 423-430
5. Ferguson M, Heath A, Johnes S, Pagliusi S, Dillner J (2006) Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 118(6):1508-1514
6. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757-1765
7. Kelly H, Riddell MA, Gidding HF, Nolan T, Gilbert GL (2002) A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 20: 3130-3136
8. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, Sargent A, Peto J (2006) HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 95: 56-61
9. Moscicki AB, Schiffman M, Kjaer S, Villa LL (2006) Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 24(Suppl 3): S42-S51
10. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527
11. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT (2003) Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10: 108-115
12. Osborne K, Gay N, Hesketh L, Morgan-Capner P, Miller E (2000) Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol 29: 362-368
13. Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC (2002) Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186: 1396-1402
14. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459-1466
15. von Krogh G, Lacey CJ, Gross G, Barrasso R, Schneider A (2001) European guideline for the management of anogenital warts. Int J STD AIDS 12(Suppl 3): 40-47
16. Wellings K, Nanchahal K, Macdowall W, McManus S, Erens B, Mercer CH, Johnson AM, Copas AJ, Korovessis C, Fenton KA, Field J (2001) Sexual behaviour in Britain: early heterosexual experience. Lancet 358: 1843- 1850
17. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS (2001) Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357: 1831-1836